Takeda goes all in on AC Immune’s active immunotherapies for Alzheimer’s with $2.2B bet
ImmunotherapyPhase 3License out/in
Takeda is putting down $100 million upfront and betting a further $2.1 billion in biobucks on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta) in the hopes that they can delay or slow Alzheimer’s disease progression. Sarah Sheikh, head of global development at Takeda, remarked “this ground-breaking treatment approach…leverages novel technology with the potential to offer patients a treatment with differentiated efficacy, safety and ease of administration.”
The agreement, announced Monday, includes an option to license AC Immune’s ACI-24.060. The therapy is being investigated in the ongoing ABATE Phase Ib/II study in people with prodromal Alzheimer’s disease and in adults with Down syndrome. AC Immune will complete the trial, with Takeda responsible for all further development and commercialisation if it exercises its option.
“We believe the maximum impact of ACI-24.060 can best be realised by partnering with Takeda at this critical juncture in its development, which will help us move rapidly into Phase III,” explained Andrea Pfeifer, CEO of AC Immune.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.